Aspirin-Induced Decline in Prostacyclin
Background. It was the purpose of this study to determine the effects of the combination of aspirin (ASA) and fish oil, which is rich in n-3 polyunsaturated fatty acids, on the eicosanoid profile of patients with coronary artery disease. Specifically, we wanted to determine whether the ASA-induced reduction in prostacyclin production is due to inhibition of endothelial cell cyclooxygenase or to reduced endoperoxide shift from platelets and whether ASA negates the potentially beneficial effects of fish oil on the eicosanoid profile. Methods and Results. Fourteen patients with clinically stable but advanced coronary artery disease received 12 g (n =8) or 16 g (n =6) of fish oil concentrate containing 6 or 8 g of n-3 fatty acids for 6 weeks. In addition to the fish oil, patients received increasing daily doses of ASA (50 mg, 100 mg, 325 mg, and 1,300 mg; the latter in four divided doses). Each dose was taken for 2 weeks. With fish oil supplementation, red blood cell phospholipid fatty acid content of arachidonic acid (AA) decreased and of eicosapentaenoic acid (EPA) increased so that EPA as a percent of AA increased from 2% to 26%. Serum thromboxane B2, which represents the production of TXA2 by maximally stimulated platelets, was suppressed by 38% on fish oil alone and by 97% or greater on all doses of ASA. Excretion of PGI2-M, the main urinary metabolite of PGI2 (derived from AA), fell from 50±4 ng/g of creatinine to 42±2 ng/g on fish oil alone (p=0.02). On 50 mg of ASA per day, PGI2-M excretion was 26±2 ng/g of creatinine (p<0.001 versus fish oil alone). On 100 mg and 325 mg of ASA per day, PGI2-M was 24±3 ng/g and 27±3 ng/g, respectively (p=NS versus value on 50 mg per day). PGI3-M, the main urinary metabolite of PGI3 (derived from EPA), increased from 0.2+±0.1 ng/g of creatinine to 4.9±0.7 ng/g on fish oil alone (p<0.001). In contrast with the marked ASA-induced decline in PGI2-M, PGI3-M excretion was not affected by the addition of ASA, even at the higher doses (4.6+0.7 ng/g and 4.9±0.5 ng/g on 325 mg per day and 325 mg four times daily, respectively).
Conclusions. Moderate-dose (325 mg per day or less) ASA taken once daily has no effect on PGI3 production despite significantly reducing PGI2 production. This suggests that endothelial cell cyclooxygenaseis minimally inhibited by such doses of ASA and that a large percent of the PGI2 produced in patients with advanced coronary artery disease derives from the transfer of prostaglandin endoperoxides from activated platelets to endothelial cells. led to a search for an optimal ASA dosage regimen that maximally suppresses TXA2 production but minimally reduces PGI2 production.18-24 The reason for the ASA-induced decline in PGI2 production is not clear, however. Although it may be due to direct inhibition of endothelial cell cyclooxygenase, fewer platelet-vessel wall interactions,25-27 and/or less endoperoxide shift from platelets after ASA may account for some part of the decline in PGI2.28-31 Endoperoxide shift, or transcellular metabolism of prostaglandin endoperoxides, which has been demonstrated in vitro,28-31 is the unidirectional transfer of prostaglandin endoperoxides, the precursors of TXA2 in the platelet and PGI2 in the endothelial cell, See p 2588 from the activated platelet to the endothelial cell, resulting in enhanced PG12 production ( Figure 1) . Thus, some of the ASA-induced decline in PGI2 production by endothelial cells may be due to the irreversible inactivation of platelet cyclooxygenase, which reduces prostaglandin endoperoxide supply to the endothelial cell during platelet-vessel wall interactions. If so, the reduction in PGI2 production caused by ASA may be unavoidable and the focus of therapy should be suppression of platelet TXA2 production, particularly when treating patients with unstable angina in whom even low levels of residual TXA2 production might be deleterious.32 Alternatively, if the ASA-induced decline in PGI2 synthesis is due to inactivation of endothelial cell cyclooxygenase, then the theoretical importance of finding an optimal low-dose ASA regimen to reduce this potentially negative effect of ASA would increase.
In this study, we used eicosapentaenoic acid (EPA) from fish oil as a "probe" to help clarify in vivo the role of endoperoxide shift in the ASAinduced decrease in PGI2 production in patients with atherosclerotic disease (Figure 1 27, 35, 37, 38 Thus, any shift of three series (EPAderived) endoperoxides from the platelet to the endothelial cell should be minimal. Therefore, if the ASA-induced decline in endothelial cell prostacyclin production is due largely to the loss of the supply of endoperoxides from platelets, then PGI2 production should decline far more than PGI1 production. If, on the other hand, the ASA-induced inhibition of PGI2 production is due primarily to endothelial cell cyclooxygenase inhibition, then PGI3 production should decline proportionally to PGI2. We report herein our findings on the effects of the combination of fish oil and increasing doses of ASA on the eicosanoid profile of 14 patients with coronary artery disease.
Methods Patient Population and Study Design
Fourteen men and two women, nonsmoking patients (ages, 49-67 years) with coronary artery disease documented by cardiac catheterization, were entered into the study. All had suffered a myocardial infarction and four had undergone coronary artery bypass surgery. None had any cardiac events within the year before entry into the study.
All patients were withdrawn from ASA-containing products for a minimum of 3 weeks. Patients were then begun on 12 or 16 g of fish oil concentrate per day (Promega capsules, provided by Warner-Lambert Co., Morris Plains, N.J.), which supplies 6 or 8 g of n-3 polyunsaturated fatty acids, of which 4.2 or 5.6 g are EPA. After 6 weeks on the fish oil alone, patients received ASA in increasing doses in addition to the fish oil. Patients took 50 mg ASA in a once-daily dose for 2 weeks followed by 100 mg and 325 mg (each dose for two weeks) and finally 325 mg four times daily for 1 week.
The following fasting laboratory data were collected at baseline (before the fish oil), after 6 weeks on fish oil alone, after 2 weeks on the 50 mg, 100 mg, and 325 mg doses of ASA, and after 1 week on the 325 mg four-times-a-day dose: complete blood count including platelet count, serum TXB2, and 24-hour urine collections for urinary eicosanoids. Red blood cell and plasma phospholipid fatty acid analyses were performed on samples taken at baseline and at week 6, week 12, and week 13 (the end) of the study. Table 2 ). These data confirmed that patients were compliant with the fish oil regimen. Furthermore, unstable levels of AA and EPA after the sixth week of the study could not have accounted for the changes in eicosanoid production described below.
Serum TXB2 production in clotted whole blood (which reflects maximal ability of the platelets to produce TXA2) fell to 63+14% of control (p<0.01) after 6 weeks of fish oil supplementation alone (Figure 2 ). On 50 mg per day of ASA, serum TXB2 production was suppressed to 3.2+1.0% of control (p<0.008). On 325 mg per day of ASA, serum TXB2 production was less than 1% of control (p=0.03 versus value on 50 mg per day) and was undetectable in most patients (Figure 2) .
In vivo production of TXA2, as estimated by urinary ll-dehydro-TXB2 excretion, fell insignificantly with the fish oil supplementation alone (598+77 ng/g versus 535+61 ng/g of creatinine) (Figure 3 ). On 50 mg per day of ASA, urinary 1 1-dehydro-TXB2 excretion fell to 168+23 ng/g of creatinine (p<0.001).
Further increases in the ASA dosage to 100 mg per day and 325 mg per day led to further slight reductions in urinary ll-dehydro-TXB2 of borderline statistical significance (pO0.03) (Figure 3) . However, on 325 mg four times daily, excretion of 11-dehydro-TXB2 did decline significantly further to 81±9 ng/g creatinine (p<0.001 versus value at time E depicted in Figure 3 ). Because serum TXB2 production by platelets was suppressed to less than 1% of control values on 325 mg per day of ASA, this further decline on 325 mg four times daily probably represents suppression of thromboxane production by nonplatelet sources that may be more resistant to the effects of ASA.
PGI2 production, as determined by PGI2-M excretion, fell slightly on the fish oil alone (50+4 to 42+2 ng/g creatinine, p=0.02) (Figure 4, left panel) . This decline was partially offset by the EPA-induced rise in PGI3 production (0.2+0.1 to 4.9+0.7 ng/g creatinine, p<O0.001) (Figure 4, right panel) .
With institution of 50 mg per day of ASA, PGI2-M excretion fell significantly from 42±2 to 26±2 ng/g creatinine, 62% of the value on fish oil alone (p<0.001) (Figure 4, left panel) The purpose of this study was to determine whether endoperoxide shift contributes significantly to the increased production of PGI2 in patients with coronary artery disease and whether the ASA-in-B duced reduction in PGI2 production in these patients is due to a decrease in the supply of prostaglandin endoperoxides from activated platelets to the endothelial cells (reduced endoperoxide shift) or to a direct inhibition of vessel wall cyclooxygenase. We used EPA as a "probe" to further clarify the reasons for the reduction in PGI2-M with ASA. Our data \c
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